Compounds > cajanine
Page last updated: 2024-12-11

cajanine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

cajanine: isolated from Cajanus cajan L.; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
CajanusgenusA plant genus of the family FABACEAE that is used for food in NIGERIA.[MeSH]FabaceaeThe large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH]
Cajanus cajanspecies[no description available]FabaceaeThe large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH]
Cajanus cajanspecies[no description available]FabaceaeThe large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH]

Cross-References

ID SourceID
PubMed CID9819225
CHEMBL ID3596977
CHEBI ID174548
SCHEMBL ID6227923
MeSH IDM0536876

Synonyms (17)

Synonym
CHEBI:174548
2-hydroxy-4-methoxy-3-(3-methyl-2-butenyl)-6-(2-phenylethenyl)benzoic acid
2-hydroxy-4-methoxy-3-(3-methylbut-2-enyl)-6-[(e)-2-phenylethenyl]benzoic acid
cajaninstilbene acid
SCHEMBL6227923
CHEMBL3596977
2-hydroxy-4-methoxy-3-(3-methylbut-2-en-1-yl)-6-[(e)-2-phenylethenyl]benzoic acid
2-hydroxy-4-methoxy-3-prenyl-6-styrylbenzoic acid
NCGC00385333-01
(e)-2-hydroxy-4-methoxy-3-(3-methylbut-2-enyl)-6-styrylbenzoic acid
FS-8514
87402-84-4
DTXSID701315168
EX-A6194
cajanine
benzoic acid, 2-hydroxy-4-methoxy-3-(3-methyl-2-buten-1-yl)-6-[(1e)-2-phenylethenyl]-
AKOS040734182

Research Excerpts

Actions

ExcerptReferenceRelevance
"Cajanine can activate the cell cycle signal transduction pathway, thus inducing cells to enter the G1/S phase and accelerating cells entering the G2/M phase."( Cajanine promotes osteogenic differentiation and proliferation of human bone marrow mesenchymal stem cells.
Fu, L; Jiao, Y; Mu, X; Xu, L; Yang, L; Yu, X; Zhang, X; Zhao, ZY, 2019)		2.68

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)		0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
stilbenoidAny olefinic compound characterised by a 1,2-diphenylethylene backbone.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (81)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347167Vero cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347153Confirmatory screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347157Confirmatory screen GU Rhodamine qHTS for Zika virus inhibitors qHTS2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347152Confirmatory screen NINDS AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347161Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347170Vero cells viability counterscreen for qRT-PCR qHTS assay of selected Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347168HepG2 cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347172Secondary qRT-PCR qHTS assay for selected Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1237613Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC62202 assessed as bacterial growth inhibition after 24 hrs by broth dilution method2015European journal of medicinal chemistry, Jul-15, Volume: 100Novel cajaninstilbene acid derivatives as antibacterial agents.
AID1769955Antibacterial activity against methicillin resistant Staphylococcus aureus ATCC515992 assessed as reduction in microbial growth after 16 to 18 hrs by microbroth dilution method2021European journal of medicinal chemistry, Nov-15, Volume: 224Synthetic cajaninstilbene acid derivatives eradicate methicillin-resistant Staphylococcus aureus persisters and biofilms.
AID1237610Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC523512 assessed as bacterial growth inhibition after 24 hrs by broth dilution method2015European journal of medicinal chemistry, Jul-15, Volume: 100Novel cajaninstilbene acid derivatives as antibacterial agents.
AID1585336Anti-biofilm activity against Pseudomonas aeruginosa PAO1 at 50 uM after 24 hrs by crystal violet staining based assay relative to control2018Journal of natural products, 12-28, Volume: 81, Issue:12
Synthesis and Biological Evaluation of Cajaninstilbene Acid and Amorfrutins A and B as Inhibitors of the Pseudomonas aeruginosa Quorum Sensing System.
AID1237611Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC425055 assessed as bacterial growth inhibition after 24 hrs by broth dilution method2015European journal of medicinal chemistry, Jul-15, Volume: 100Novel cajaninstilbene acid derivatives as antibacterial agents.
AID1714230Destabilization of CSGalNacT-1 in human Huh7.5 cells assessed as down regulation of CSGalNacT-1 protein levels at 25 uM measured after 24 hrs in presence of protease inhibitor MG132 by Western blot analysis2016Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22
Design and Synthesis of Cajanine Analogues against Hepatitis C Virus through Down-Regulating Host Chondroitin Sulfate N-Acetylgalactosaminyltransferase 1.
AID1714233Antiviral activity against HCV subtype 2a J6/JFH/JC1 infected in human Huh7.5 cells assessed as reduction in viral RNA levels measured after 72 hrs by qRT-PCR analysis2016Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22
Design and Synthesis of Cajanine Analogues against Hepatitis C Virus through Down-Regulating Host Chondroitin Sulfate N-Acetylgalactosaminyltransferase 1.
AID1714209Synergistic antiviral activity against HCV J6/JFH/JC1 infected in human HuH7.5 cells assessed as inhibition of viral protein levels at 6.25 uM in presence of sofosbuvir measured after 72 hrs by western blot analysis2016Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22
Design and Synthesis of Cajanine Analogues against Hepatitis C Virus through Down-Regulating Host Chondroitin Sulfate N-Acetylgalactosaminyltransferase 1.
AID1237612Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC513045 assessed as bacterial growth inhibition after 24 hrs by broth dilution method2015European journal of medicinal chemistry, Jul-15, Volume: 100Novel cajaninstilbene acid derivatives as antibacterial agents.
AID1714224Antiviral activity against HCV subgenomic replicon harboring I377-3'del.S infected in human GS4.3 cells assessed as inhibition of viral replication at 0.23 to 18.52 uM after 72 hrs by qRT-PCR analysis2016Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22
Design and Synthesis of Cajanine Analogues against Hepatitis C Virus through Down-Regulating Host Chondroitin Sulfate N-Acetylgalactosaminyltransferase 1.
AID1714222Antiviral activity against HCV infected in human HuH7.5 cells assessed as inhibition of viral RNA levels during early stage at 6.25 to 25 uM incubated for 2 hrs prior to compound washout followed by supplementation of fresh culture medium and measured aft2016Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22
Design and Synthesis of Cajanine Analogues against Hepatitis C Virus through Down-Regulating Host Chondroitin Sulfate N-Acetylgalactosaminyltransferase 1.
AID1237614Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC51033 assessed as bacterial growth inhibition after 24 hrs by broth dilution method2015European journal of medicinal chemistry, Jul-15, Volume: 100Novel cajaninstilbene acid derivatives as antibacterial agents.
AID1237604Antibacterial activity against Staphylococcus epidermidis ATCC12228 assessed as bacterial growth inhibition after 24 hrs by broth dilution method2015European journal of medicinal chemistry, Jul-15, Volume: 100Novel cajaninstilbene acid derivatives as antibacterial agents.
AID1714231Inhibition of HCV NS5B polymerase2016Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22
Design and Synthesis of Cajanine Analogues against Hepatitis C Virus through Down-Regulating Host Chondroitin Sulfate N-Acetylgalactosaminyltransferase 1.
AID1607893Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production at 10 uM preincubated for 2 hrs followed by LPS stimulation measured after 24 hrs by Griess reagent based assay relative to control2019European journal of medicinal chemistry, Oct-01, Volume: 179Human disorders associated with inflammation and the evolving role of natural products to overcome.
AID1714218Antiviral activity against HCV J6/JFH/JC1 harboring D168V mutant infected in human Huh7.5 cells assessed as inhibition of viral replication measured after 72 hrs by qRT-PCR analysis2016Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22
Design and Synthesis of Cajanine Analogues against Hepatitis C Virus through Down-Regulating Host Chondroitin Sulfate N-Acetylgalactosaminyltransferase 1.
AID1769959Antibacterial activity against methicillin resistant Staphylococcus aureus ATCC48966 assessed as reduction in microbial growth after 16 to 18 hrs by microbroth dilution method2021European journal of medicinal chemistry, Nov-15, Volume: 224Synthetic cajaninstilbene acid derivatives eradicate methicillin-resistant Staphylococcus aureus persisters and biofilms.
AID1769958Antibacterial activity against methicillin resistant Staphylococcus aureus ATCC48073 assessed as reduction in microbial growth after 16 to 18 hrs by microbroth dilution method2021European journal of medicinal chemistry, Nov-15, Volume: 224Synthetic cajaninstilbene acid derivatives eradicate methicillin-resistant Staphylococcus aureus persisters and biofilms.
AID1237606Antibacterial activity against Escherichia coli ATCC25922 assessed as bacterial growth inhibition after 24 hrs by broth dilution method2015European journal of medicinal chemistry, Jul-15, Volume: 100Novel cajaninstilbene acid derivatives as antibacterial agents.
AID1714238Destabilization of CSGalNacT-1 in human Huh7.5 cells assessed as reduction in CSGalNacT-1 mRNA levels at 6.25 to 100 uM measured after 72 hrs by qRT-PCR analysis2016Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22
Design and Synthesis of Cajanine Analogues against Hepatitis C Virus through Down-Regulating Host Chondroitin Sulfate N-Acetylgalactosaminyltransferase 1.
AID1714217Antiviral activity against HCV J6/JFH/JC1 harboring S282T mutant infected in human Huh7.5 cells assessed as inhibition of viral replication measured after 72 hrs by qRT-PCR analysis2016Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22
Design and Synthesis of Cajanine Analogues against Hepatitis C Virus through Down-Regulating Host Chondroitin Sulfate N-Acetylgalactosaminyltransferase 1.
AID1237607Antibacterial activity against Proteus vulgaris ATCC49101 assessed as bacterial growth inhibition after 24 hrs by broth dilution method2015European journal of medicinal chemistry, Jul-15, Volume: 100Novel cajaninstilbene acid derivatives as antibacterial agents.
AID1714219Antiviral activity against HCV J6/JFH/JC1 harboring A156T mutant infected in human Huh7.5 cells assessed as inhibition of viral replication measured after 72 hrs by qRT-PCR analysis2016Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22
Design and Synthesis of Cajanine Analogues against Hepatitis C Virus through Down-Regulating Host Chondroitin Sulfate N-Acetylgalactosaminyltransferase 1.
AID1769963Antibacterial activity against Pseudomonas aeruginosa ATCC27853 assessed as reduction in microbial growth after 16 to 18 hrs by microbroth dilution method2021European journal of medicinal chemistry, Nov-15, Volume: 224Synthetic cajaninstilbene acid derivatives eradicate methicillin-resistant Staphylococcus aureus persisters and biofilms.
AID1714235Antiviral activity against wild-type HCV infected in human HuH7.5 cells assessed as reduction in viral protein levels at 6.25 to 100 uM measured after 72 hrs by Western blot assay2016Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22
Design and Synthesis of Cajanine Analogues against Hepatitis C Virus through Down-Regulating Host Chondroitin Sulfate N-Acetylgalactosaminyltransferase 1.
AID1769954Antibacterial activity against methicillin resistant Staphylococcus aureus ATCC513045 assessed as reduction in microbial growth after 16 to 18 hrs by microbroth dilution method2021European journal of medicinal chemistry, Nov-15, Volume: 224Synthetic cajaninstilbene acid derivatives eradicate methicillin-resistant Staphylococcus aureus persisters and biofilms.
AID1714211Synergistic antiviral activity against HCV J6/JFH/JC1 infected in human HuH7.5 cells assessed as combination index measured after 72 hrs in presence of daclatasvir by Chou-Talalay method2016Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22
Design and Synthesis of Cajanine Analogues against Hepatitis C Virus through Down-Regulating Host Chondroitin Sulfate N-Acetylgalactosaminyltransferase 1.
AID1769957Antibacterial activity against methicillin resistant Staphylococcus aureus ATCC49025 assessed as reduction in microbial growth after 16 to 18 hrs by microbroth dilution method2021European journal of medicinal chemistry, Nov-15, Volume: 224Synthetic cajaninstilbene acid derivatives eradicate methicillin-resistant Staphylococcus aureus persisters and biofilms.
AID1714239Destabilization of CSGalNacT-1 in human Huh7.5 cells assessed as reduction in CSGalNacT-1 expression measured after 72 hrs by Western blot analysis2016Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22
Design and Synthesis of Cajanine Analogues against Hepatitis C Virus through Down-Regulating Host Chondroitin Sulfate N-Acetylgalactosaminyltransferase 1.
AID1714202Inhibition of HCV NS3/4a protease2016Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22
Design and Synthesis of Cajanine Analogues against Hepatitis C Virus through Down-Regulating Host Chondroitin Sulfate N-Acetylgalactosaminyltransferase 1.
AID1714229Effect on CD36 expression level in human Huh7.5 cells at 6.25 to 25 uM by Western blot analysis2016Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22
Design and Synthesis of Cajanine Analogues against Hepatitis C Virus through Down-Regulating Host Chondroitin Sulfate N-Acetylgalactosaminyltransferase 1.
AID1714236Inhibition of HCV NS5A2016Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22
Design and Synthesis of Cajanine Analogues against Hepatitis C Virus through Down-Regulating Host Chondroitin Sulfate N-Acetylgalactosaminyltransferase 1.
AID1714228Effect on Hsc70 expression level in human Huh7.5 cells at 6.25 to 25 uM by Western blot analysis2016Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22
Design and Synthesis of Cajanine Analogues against Hepatitis C Virus through Down-Regulating Host Chondroitin Sulfate N-Acetylgalactosaminyltransferase 1.
AID1714208Synergistic antiviral activity against HCV J6/JFH/JC1 infected in human HuH7.5 cells assessed as inhibition of viral protein levels at 6.25 uM in presence of daclatasvir measured after 72 hrs by western blot analysis2016Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22
Design and Synthesis of Cajanine Analogues against Hepatitis C Virus through Down-Regulating Host Chondroitin Sulfate N-Acetylgalactosaminyltransferase 1.
AID1607892Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production at 20 uM preincubated for 2 hrs followed by LPS stimulation measured after 24 hrs by Griess reagent based assay relative to control2019European journal of medicinal chemistry, Oct-01, Volume: 179Human disorders associated with inflammation and the evolving role of natural products to overcome.
AID1714216Resistance ratio of EC50 for antiviral activity against HCV J6/JFH/JC1 harboring D168V mutant infected in human Huh7.5 cells to EC50 for antiviral activity against wild-type HCV J6/JFH/JC1 infected in human Huh7.5 cells2016Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22
Design and Synthesis of Cajanine Analogues against Hepatitis C Virus through Down-Regulating Host Chondroitin Sulfate N-Acetylgalactosaminyltransferase 1.
AID1714240Destabilization of CSGalNacT-1 in HCV infected human HuH7.5 cells assessed as reduction in CSGalNacT-1 protein levels measured after 72 hrs by Western blot analysis2016Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22
Design and Synthesis of Cajanine Analogues against Hepatitis C Virus through Down-Regulating Host Chondroitin Sulfate N-Acetylgalactosaminyltransferase 1.
AID1237608Antibacterial activity against Pseudomonas aeruginosa ATCC2785 assessed as bacterial growth inhibition after 24 hrs by broth dilution method2015European journal of medicinal chemistry, Jul-15, Volume: 100Novel cajaninstilbene acid derivatives as antibacterial agents.
AID1237609Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC43300 assessed as bacterial growth inhibition after 24 hrs by broth dilution method2015European journal of medicinal chemistry, Jul-15, Volume: 100Novel cajaninstilbene acid derivatives as antibacterial agents.
AID1714212Synergistic antiviral activity against HCV J6/JFH/JC1 infected in human HuH7.5 cells assessed as combination index measured after 72 hrs in presence of sofosbuvir by Chou-Talalay method2016Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22
Design and Synthesis of Cajanine Analogues against Hepatitis C Virus through Down-Regulating Host Chondroitin Sulfate N-Acetylgalactosaminyltransferase 1.
AID1714213Synergistic antiviral activity against HCV J6/JFH/JC1 infected in human HuH7.5 cells assessed as combination index measured after 72 hrs in presence of simeprevir by Chou-Talalay method2016Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22
Design and Synthesis of Cajanine Analogues against Hepatitis C Virus through Down-Regulating Host Chondroitin Sulfate N-Acetylgalactosaminyltransferase 1.
AID1769953Antibacterial activity against methicillin resistant Staphylococcus aureus ATCC 52056 assessed as reduction in microbial growth after 16 to 18 hrs by microbroth dilution method2021European journal of medicinal chemistry, Nov-15, Volume: 224Synthetic cajaninstilbene acid derivatives eradicate methicillin-resistant Staphylococcus aureus persisters and biofilms.
AID1769960Antibacterial activity against methicillin resistant Staphylococcus aureus ATCC49008 assessed as reduction in microbial growth after 16 to 18 hrs by microbroth dilution method2021European journal of medicinal chemistry, Nov-15, Volume: 224Synthetic cajaninstilbene acid derivatives eradicate methicillin-resistant Staphylococcus aureus persisters and biofilms.
AID1714220Antiviral activity against wild-type HCV J6/JFH/JC1 infected in human Huh7.5 cells assessed as inhibition of viral replication measured after 72 hrs by qRT-PCR analysis2016Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22
Design and Synthesis of Cajanine Analogues against Hepatitis C Virus through Down-Regulating Host Chondroitin Sulfate N-Acetylgalactosaminyltransferase 1.
AID1769950Antibacterial activity against Staphylococcus aureus ATCC 25923 assessed as reduction in microbial growth after 16 to 18 hrs by microbroth dilution method2021European journal of medicinal chemistry, Nov-15, Volume: 224Synthetic cajaninstilbene acid derivatives eradicate methicillin-resistant Staphylococcus aureus persisters and biofilms.
AID1714232Selectivity index, ratio of CC50 for cytotoxicity against human Huh7.5 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay to EC50 for antiviral activity against HCV genotype 2a J6/JFH/JC1 infected in human Huh7.5 cells assesse2016Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22
Design and Synthesis of Cajanine Analogues against Hepatitis C Virus through Down-Regulating Host Chondroitin Sulfate N-Acetylgalactosaminyltransferase 1.
AID1607863Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production at 50 uM preincubated for 2 hrs followed by LPS stimulation measured after 24 hrs by Griess reagent based assay relative to control2019European journal of medicinal chemistry, Oct-01, Volume: 179Human disorders associated with inflammation and the evolving role of natural products to overcome.
AID1769951Antibacterial activity against methicillin resistant Staphylococcus aureus ATCC 43300 assessed as reduction in microbial growth after 16 to 18 hrs by microbroth dilution method2021European journal of medicinal chemistry, Nov-15, Volume: 224Synthetic cajaninstilbene acid derivatives eradicate methicillin-resistant Staphylococcus aureus persisters and biofilms.
AID1769962Antibacterial activity against Escherichia coli ATCC25922 assessed as reduction in microbial growth after 16 to 18 hrs by microbroth dilution method2021European journal of medicinal chemistry, Nov-15, Volume: 224Synthetic cajaninstilbene acid derivatives eradicate methicillin-resistant Staphylococcus aureus persisters and biofilms.
AID1714237Destabilization of CSGalNacT-1 in HCV infected human HuH7.5 cells assessed as reduction in CSGalNacT-1 mRNA levels at 6.25 to 100 uM measured after 72 hrs by qRT-PCR analysis2016Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22
Design and Synthesis of Cajanine Analogues against Hepatitis C Virus through Down-Regulating Host Chondroitin Sulfate N-Acetylgalactosaminyltransferase 1.
AID1769956Antibacterial activity against methicillin resistant Staphylococcus aureus ATCC49800 assessed as reduction in microbial growth after 16 to 18 hrs by microbroth dilution method2021European journal of medicinal chemistry, Nov-15, Volume: 224Synthetic cajaninstilbene acid derivatives eradicate methicillin-resistant Staphylococcus aureus persisters and biofilms.
AID1714241Destabilization of CSGalNacT-1 in human Huh7.5 cells assessed as reduction in CSGalNacT-1 mRNA levels by gene chip assay2016Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22
Design and Synthesis of Cajanine Analogues against Hepatitis C Virus through Down-Regulating Host Chondroitin Sulfate N-Acetylgalactosaminyltransferase 1.
AID1769952Antibacterial activity against methicillin resistant Staphylococcus aureus ATCC 62202 assessed as reduction in microbial growth after 16 to 18 hrs by microbroth dilution method2021European journal of medicinal chemistry, Nov-15, Volume: 224Synthetic cajaninstilbene acid derivatives eradicate methicillin-resistant Staphylococcus aureus persisters and biofilms.
AID1237615Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC52056 assessed as bacterial growth inhibition after 24 hrs by broth dilution method2015European journal of medicinal chemistry, Jul-15, Volume: 100Novel cajaninstilbene acid derivatives as antibacterial agents.
AID1714234Cytotoxicity against human Huh7.5 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2016Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22
Design and Synthesis of Cajanine Analogues against Hepatitis C Virus through Down-Regulating Host Chondroitin Sulfate N-Acetylgalactosaminyltransferase 1.
AID1714215Resistance ratio of EC50 for antiviral activity against HCV J6/JFH/JC1 harboring A156T mutant infected in human Huh7.5 cells to EC50 for antiviral activity against wild-type HCV J6/JFH/JC1 infected in human Huh7.5 cells2016Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22
Design and Synthesis of Cajanine Analogues against Hepatitis C Virus through Down-Regulating Host Chondroitin Sulfate N-Acetylgalactosaminyltransferase 1.
AID1714221Antiviral activity against HCV infected in human HuH7.5 cells assessed as inhibition of viral protein level during early stage at 6.25 to 25 uM incubated for 2 hrs prior to compound washout followed by supplementation of fresh culture medium and measured 2016Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22
Design and Synthesis of Cajanine Analogues against Hepatitis C Virus through Down-Regulating Host Chondroitin Sulfate N-Acetylgalactosaminyltransferase 1.
AID1769961Antibacterial activity against methicillin resistant Staphylococcus aureus ATCC48706 assessed as reduction in microbial growth after 16 to 18 hrs by microbroth dilution method2021European journal of medicinal chemistry, Nov-15, Volume: 224Synthetic cajaninstilbene acid derivatives eradicate methicillin-resistant Staphylococcus aureus persisters and biofilms.
AID1237617Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC510019 assessed as bacterial growth inhibition after 24 hrs by broth dilution method2015European journal of medicinal chemistry, Jul-15, Volume: 100Novel cajaninstilbene acid derivatives as antibacterial agents.
AID1237605Antibacterial activity against Bacillus subtilis ATCC6633 assessed as bacterial growth inhibition after 24 hrs by broth dilution method2015European journal of medicinal chemistry, Jul-15, Volume: 100Novel cajaninstilbene acid derivatives as antibacterial agents.
AID1714210Synergistic antiviral activity against HCV J6/JFH/JC1 infected in human HuH7.5 cells assessed as inhibition of viral protein levels at 6.25 uM in presence of simeprevir measured after 72 hrs by western blot analysis2016Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22
Design and Synthesis of Cajanine Analogues against Hepatitis C Virus through Down-Regulating Host Chondroitin Sulfate N-Acetylgalactosaminyltransferase 1.
AID1714214Resistance ratio of EC50 for antiviral activity against HCV J6/JFH/JC1 harboring S282T mutant infected in human Huh7.5 cells to EC50 for antiviral activity against wild-type HCV J6/JFH/JC1 infected in human Huh7.5 cells2016Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22
Design and Synthesis of Cajanine Analogues against Hepatitis C Virus through Down-Regulating Host Chondroitin Sulfate N-Acetylgalactosaminyltransferase 1.
AID1237616Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC515992 assessed as bacterial growth inhibition after 24 hrs by broth dilution method2015European journal of medicinal chemistry, Jul-15, Volume: 100Novel cajaninstilbene acid derivatives as antibacterial agents.
AID1769964Antibacterial activity against Enterococcus faecalis ATCC29212 assessed as reduction in microbial growth after 16 to 18 hrs by microbroth dilution method2021European journal of medicinal chemistry, Nov-15, Volume: 224Synthetic cajaninstilbene acid derivatives eradicate methicillin-resistant Staphylococcus aureus persisters and biofilms.
AID1540904Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated NO production at 15 uM preincubated with LPS and measured after 20 hrs by Griess reagent-based assay relative to control
AID1237603Antibacterial activity against Staphylococcus aureus ATCC25923 assessed as bacterial growth inhibition after 24 hrs by broth dilution method2015European journal of medicinal chemistry, Jul-15, Volume: 100Novel cajaninstilbene acid derivatives as antibacterial agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (18.75)29.6817
2010's8 (50.00)24.3611
2020's5 (31.25)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (6.25%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (93.75%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate
[no description available]		3.3110catechin
aspirin
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5). acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.. acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.		3.3110benzoic acids;
phenyl acetates;
salicylates		anticoagulant;
antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
EC 1.1.1.188 (prostaglandin-F synthase) inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
plant activator;
platelet aggregation inhibitor;
prostaglandin antagonist;
teratogenic agent
celecoxib
[no description available]		3.3110organofluorine compound;
pyrazoles;
sulfonamide;
toluenes		cyclooxygenase 2 inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
ciprofloxacin
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.		2.3110aminoquinoline;
cyclopropanes;
fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone;
zwitterion		antibacterial drug;
antiinfective agent;
antimicrobial agent;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
environmental contaminant;
topoisomerase IV inhibitor;
xenobiotic
norfloxacin
Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.. norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.		2.5820fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone		antibacterial drug;
DNA synthesis inhibitor;
environmental contaminant;
xenobiotic
penicillin g
Penicillin G: A penicillin derivative commonly used in the form of its sodium or potassium salts in the treatment of a variety of infections. It is effective against most gram-positive bacteria and against gram-negative cocci. It has also been used as an experimental convulsant because of its actions on GAMMA-AMINOBUTYRIC ACID mediated synaptic transmission.. benzylpenicillin : A penicillin in which the substituent at position 6 of the penam ring is a phenylacetamido group.		2.1110penicillin allergen;
penicillin		antibacterial drug;
drug allergen;
epitope
ampicillin
Ampicillin: Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.. ampicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-phenylacetamido group.		2.3110beta-lactam antibiotic;
penicillin allergen;
penicillin		antibacterial drug
quinazolines
Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.		2.610azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
quinazolines
vancomycin
Vancomycin: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.. vancomycin : A complex glycopeptide from Streptomyces orientalis. It inhibits a specific step in the synthesis of the peptidoglycan layer in the Gram-positive bacteria Staphylococcus aureus and Clostridium difficile.		2.3110glycopeptideantibacterial drug;
antimicrobial agent;
bacterial metabolite
piperacillin
Piperacillin: Semisynthetic, broad-spectrum, AMPICILLIN derived ureidopenicillin antibiotic proposed for PSEUDOMONAS infections. It is also used in combination with other antibiotics.. piperacillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-[(4-ethyl-2,3-dioxopiperazin-1-yl)carboxamido]-2-phenylacetamido group.		2.3110penicillin allergen;
penicillin		antibacterial drug
betulinic acid
[no description available]		3.3110hydroxy monocarboxylic acid;
pentacyclic triterpenoid		anti-HIV agent;
anti-inflammatory agent;
antimalarial;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
plant metabolite
gentamicin c1a
[no description available]		2.3110gentamycin C
zaluzanin C
zaluzanin C: from Ainsliaea yunnanensis and Zaluzania robinsonii; structure in first source. zaluzanin C : A sesquiterpene lactone that is decahydroazuleno[4,5-b]furan-2(3H)-one substituted by methylidene groups at positions 3, 6 and 9 and a hydroxy group at position 8.		3.3110gamma-lactone;
guaiane sesquiterpenoid;
organic heterotricyclic compound;
secondary alcohol;
sesquiterpene lactone		EC 1.14.13.39 (nitric oxide synthase) inhibitor;
metabolite
syringaresinol
[no description available]		3.3110aromatic ether;
furofuran;
lignan;
polyether;
polyphenol		plant metabolite
bekanamycin
bekanamycin: kanendomycin is the sulfate of bekanamycin; RN given refers to parent cpd; structure		2.3110kanamycins
resveratrol
trans-resveratrol : A resveratrol in which the double bond has E configuration.		3.3110resveratrolantioxidant;
phytoalexin;
plant metabolite;
quorum sensing inhibitor;
radical scavenger
diethylstilbestrol
Diethylstilbestrol: A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. (Merck, 11th ed). diethylstilbestrol : An olefinic compound that is trans-hex-3-ene in which the hydrogens at positions 3 and 4 have been replaced by p-hydroxyphenyl groups.		3.4870olefinic compound;
polyphenol		antifungal agent;
antineoplastic agent;
autophagy inducer;
calcium channel blocker;
carcinogenic agent;
EC 1.1.1.146 (11beta-hydroxysteroid dehydrogenase) inhibitor;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
endocrine disruptor;
xenoestrogen
stilbenes
Stilbenes: Organic compounds that contain 1,2-diphenylethylene as a functional group.. trans-stilbene : The trans-isomer of stilbene.		2.4820stilbene
isoliquiritigenin
[no description available]		3.3110chalconesantineoplastic agent;
biological pigment;
EC 1.14.18.1 (tyrosinase) inhibitor;
GABA modulator;
geroprotector;
metabolite;
NMDA receptor antagonist
curcumin
Curcumin: A yellow-orange dye obtained from tumeric, the powdered root of CURCUMA longa. It is used in the preparation of curcuma paper and the detection of boron. Curcumin appears to possess a spectrum of pharmacological properties, due primarily to its inhibitory effects on metabolic enzymes.. curcumin : A beta-diketone that is methane in which two of the hydrogens are substituted by feruloyl groups. A natural dyestuff found in the root of Curcuma longa.		3.3110aromatic ether;
beta-diketone;
diarylheptanoid;
enone;
polyphenol		anti-inflammatory agent;
antifungal agent;
antineoplastic agent;
biological pigment;
contraceptive drug;
dye;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
EC 1.8.1.9 (thioredoxin reductase) inhibitor;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
flavouring agent;
food colouring;
geroprotector;
hepatoprotective agent;
immunomodulator;
iron chelator;
ligand;
lipoxygenase inhibitor;
metabolite;
neuroprotective agent;
nutraceutical;
radical scavenger
telaprevir
[no description available]		2.1310cyclopentapyrrole;
cyclopropanes;
oligopeptide;
pyrazines		antiviral drug;
hepatitis C protease inhibitor;
peptidomimetic
formononetin
[no description available]		2.05104'-methoxyisoflavones;
7-hydroxyisoflavones		phytoestrogen;
plant metabolite
quercetin 3-o-methyl ether
quercetin 3-O-methyl ether: from Rhamnus species; structure in first source. 3',4',5,7-tetrahydroxy-3-methoxyflavone : A tetrahydroxyflavone having the 4-hydroxy groups located at the 3'- 4'- 5- and 7-positions as well as a methoxy group at the 2-position.		3.3110monomethoxyflavone;
tetrahydroxyflavone		antimicrobial agent;
metabolite
genistein
[no description available]		2.05107-hydroxyisoflavonesantineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
geroprotector;
human urinary metabolite;
phytoestrogen;
plant metabolite;
tyrosine kinase inhibitor
isobavachalcone
isobavachalcone: RN given for (E)-isomer; structure in first source. isobavachalcone : A member of the class of chalcones that is trans-chalcone substituted by hydroxy groups at positions 4, 2' and 4' and a prenyl group at position 3'.		3.3110chalcones;
polyphenol		antibacterial agent;
metabolite;
platelet aggregation inhibitor
norathyriol
norathyriol: from Gentinanaceae; has vasorelaxing action on rat thoracic aorta; structure given in first source. norathyriol : A member of the class of xanthones that is 9H-xanthen-9-one substituted by hydroxy groups at positions 1, 3, 6 and 7. Isolated from Garcinia mangostana and Maclura pomifera, it exhibits inhibitory activity against protein kinase C.		3.3110polyphenol;
xanthones		antineoplastic agent;
EC 2.7.11.13 (protein kinase C) inhibitor;
plant metabolite
myricitrin
myricitrin: isolated from root bark of Myrica cerifera L.; structure. myricitrin : A glycosyloxyflavone that consists of myricetin attached to a alpha-L-rhamnopyranosyl residue at position 3 via a glycosidic linkage. Isolated from Myrica cerifera, it exhibits anti-allergic activity.		3.3110alpha-L-rhamnoside;
glycosyloxyflavone;
monosaccharide derivative;
pentahydroxyflavone		anti-allergic agent;
EC 1.14.13.39 (nitric oxide synthase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
plant metabolite
acteoside
acteoside: a protein kinase C inhibitor with hepatoprotective, anti-asthmatic, and analgesic activities; a phenylethanoid glycoside related to isoacteoside; from leaves of Lippia multiflora (Verbenaceae). acteoside : A glycoside that is the alpha-L-rhamnosyl-(1->3)-beta-D-glucoside of hydroxytyrosol in which the hydroxy group at position 4 of the glucopyranosyl moiety has undergone esterification by formal condensation with trans-caffeic acid.		3.3110catechols;
cinnamate ester;
disaccharide derivative;
glycoside;
polyphenol		anti-inflammatory agent;
antibacterial agent;
antileishmanial agent;
neuroprotective agent;
plant metabolite
muromonab-cd3
cudraflavone B: antiproliferative from Cudrania tricuspidata. cudraflavone B : An extended flavonoid that consists of a pyranochromane skeleton that is 2H,6H-pyrano[3,2-g]chromen-6-one substituted by geminal methyl groups at position 2, a 2,4-dihydroxyphenyl group at position 8, a hydroxy group at position 5 and a prenyl group at position 7. Isolated from Morus alba and Morus species it exhibits anti-inflammatory activity.		3.3110extended flavonoid;
pyranochromane;
trihydroxyflavone		anti-inflammatory agent;
plant metabolite
ergosterol-5,8-peroxide
ergosterol-5,8-peroxide: also inhibits sulfatase; isolated from fungus Cercospora kikuchii; structure given in first source. ergosterol peroxide : An ergostanoid that is ergosta-6,22-dien-3-ol with a peroxy group between positions 5 and 8 (the 3beta,5alpha,8alpha,22E stereoisomer). Isolated from Ganoderma lucidum and Cordyceps sinensis, it exhibits antimycobacterial, trypanocidal and antineoplastic activities.		3.31103beta-sterol;
ergostanoid;
organic peroxide;
phytosterols		antimycobacterial drug;
antineoplastic agent;
metabolite;
trypanocidal drug
guttiferone e
guttiferone E: isolated from the fruits of Garcinia pyrifera collected in Malaysia; structure in first source		3.3110
lichexanthone
lichexanthone: a dihydropyranexanthone derived from the natural xanthone; structure in first source. lichexanthone : A member of the class of xanthones that is 9H-xanthen-9-one substituted by a hydroxy group at position 1, a methyl group at position 8 and methoxy groups at positions 3 and 6. It has been isolated from the bark of Cupania cinerea.		3.3110aromatic ether;
phenols;
xanthones		plant metabolite
1,3,5,6-tetrahydroxyxanthone
1,3,5,6-tetrahydroxyxanthone: from roots of Cudrania cochinchinensis		3.3110
Norartocarpetin
[no description available]		3.3110flavones
24-ethyl-4-cholesten-3-one
stigmast-4-en-3-one: from the bark of Anacardium occidentale (cashew); structure in first source		3.3110C29-steroid;
steroid		metabolite
lyoniside
daucosterol : A steroid saponin that is sitosterol attached to a beta-D-glucopyranosyl residue at position 3 via a glycosidic linkage. It has bee isolated from Panax japonicus var. major and Breynia fruticosa.		3.3110beta-D-glucoside;
monosaccharide derivative;
steroid saponin		plant metabolite
13-oxo-9,11-octadecadienoic acid
13-oxo-9Z,11E-ODE : An oxooctadecadienoic acid that consists of 9Z,11E-octadecadienoic acid bearing an additional 13-keto substituent. In addtion it has been found as a natural product found in Carthamus oxyacantha.		3.311013-oxo-9,11-octadecadienoic acidmetabolite;
mouse metabolite
2,4,2',4'-Tetrahydroxychalcone
[no description available]		3.3110chalcones
alisporivir
alisporivir: nonimmunosuppressive cyclosporin analog; structure/sequence in first source		2.1310homodetic cyclic peptideanticoronaviral agent
chikusetsu saponin iva
chikusetsu saponin IVa: from the tubers of Hemsleya pengxianensis (Cucurbitaceae)		3.3110triterpenoid saponinmetabolite
amorfrutin a
amorfrutin A: an antidiabetic agent that inhibits NF-kappaB activation; structure in first source		2.5520stilbenoid
Norartocarpanone
[no description available]		3.3110flavanones
(E)-1,7-Bis(4-hydroxyphenyl)hept-4-en-3-one
[no description available]		3.3110diarylheptanoid
amorfrutin b
amorfrutin B: structure in first source		2.1710
simeprevir
[no description available]		2.1310azamacrocycle;
lactam
bms-790052
daclatasvir: an HCV NS5A inhibitor. daclatasvir : A member of the class of biphenyls that is a potent inhibitor of nonstructural protein 5A and is used (as its hydrochloride salt) for treatment of hepatitis C.		2.1310biphenyls;
carbamate ester;
carboxamide;
imidazoles;
valine derivative		antiviral drug;
nonstructural protein 5A inhibitor
sofosbuvir
Sofosbuvir: A uridine monophosphate analog inhibitor of HEPATITIS C VIRUS (HCV) polymerase NS5B that is used as an ANTIVIRAL AGENT in the treatment of CHRONIC HEPATITIS C.. sofosbuvir : A nucleotide conjugate that is used in combination with ledipasvir (under the trade name Harvoni) for the treatment of chronic hepatitis C genotype 1 infection.		2.1310isopropyl ester;
L-alanyl ester;
nucleotide conjugate;
organofluorine compound;
phosphoramidate ester		antiviral drug;
hepatitis C protease inhibitor;
prodrug
salicylates
Salicylates: The salts or esters of salicylic acids, or salicylate esters of an organic acid. Some of these have analgesic, antipyretic, and anti-inflammatory activities by inhibiting prostaglandin synthesis.. hydroxybenzoate : Any benzoate derivative carrying a single carboxylate group and at least one hydroxy substituent.. salicylates : Any salt or ester arising from reaction of the carboxy group of salicylic acid, or any ester resulting from the condensation of the phenolic hydroxy group of salicylic acid with an organic acid.. salicylate : A monohydroxybenzoate that is the conjugate base of salicylic acid.		2.1310monohydroxybenzoateplant metabolite
phytoestrogens
Phytoestrogens: Compounds derived from plants, primarily ISOFLAVONES that mimic or modulate endogenous estrogens, usually by binding to ESTROGEN RECEPTORS.		2.4420
3-hydroxy-4-prenyl-5-methoxystilbene-2-carboxylic acid
3-hydroxy-4-prenyl-5-methoxystilbene-2-carboxylic acid: isolated from pigeonpea, Cajanus cajan; structure in first source		2.1310
rifampin
Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)		2.3110cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion		angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Rheumatoid Arthritis
[description not available]		03.1210
Innate Inflammatory Response
[description not available]		03.1210
Benign Neoplasms
[description not available]		03.5520
Dermatoses
[description not available]		03.5720
Arthritis, Rheumatoid
A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.		03.1210
Cardiovascular Diseases
Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.		03.1210
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		03.1210
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		03.5520
Skin Diseases
Diseases involving the DERMIS or EPIDERMIS.		03.5720
Congenital Zika Syndrome
[description not available]		02.2510
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.6920
Zika Virus Infection
A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.		02.2510
Infections, Staphylococcal
[description not available]		02.3110
Staphylococcal Infections
Infections with bacteria of the genus STAPHYLOCOCCUS.		02.3110
Infections, Coronavirus
[description not available]		02.610
Coronavirus Infections
Virus diseases caused by the CORONAVIRUS genus. Some specifics include transmissible enteritis of turkeys (ENTERITIS, TRANSMISSIBLE, OF TURKEYS); FELINE INFECTIOUS PERITONITIS; and transmissible gastroenteritis of swine (GASTROENTERITIS, TRANSMISSIBLE, OF SWINE).		02.610
Breast Cancer
[description not available]		02.1310
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.1310
Aging
The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.		02.0510
Cognition Disorders
Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.		02.0510
Bone Cancer
[description not available]		02.0310
Osteogenic Sarcoma
[description not available]		02.0310
Bone Neoplasms
Tumors or cancer located in bone tissue or specific BONES.		02.0310
Osteosarcoma
A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)		02.0310